397 related articles for article (PubMed ID: 10952592)
1. Interactions between triazoles and amphotericin B against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Caselli F; Novelli A; Fallani S; Giannini D; Arzeni D; Di Cesare S; Di Francesco LF; Fortuna M; Giacometti A; Carle F; Mazzei T; Scalise G
Antimicrob Agents Chemother; 2000 Sep; 44(9):2435-41. PubMed ID: 10952592
[TBL] [Abstract][Full Text] [Related]
2. Interactions of posaconazole and flucytosine against Cryptococcus neoformans.
Barchiesi F; Schimizzi AM; Najvar LK; Bocanegra R; Caselli F; Di Cesare S; Giannini D; Di Francesco LF; Giacometti A; Carle F; Scalise G; Graybill JR
Antimicrob Agents Chemother; 2001 May; 45(5):1355-9. PubMed ID: 11302795
[TBL] [Abstract][Full Text] [Related]
3. Terbinafine inhibits Cryptococcus neoformans growth and modulates fungal morphology.
Guerra CR; Ishida K; Nucci M; Rozental S
Mem Inst Oswaldo Cruz; 2012 Aug; 107(5):582-90. PubMed ID: 22850947
[TBL] [Abstract][Full Text] [Related]
4. Synergistic effect of pyrvinium pamoate and posaconazole against
Li Y; Li S; Chen M; Xiao J; Fang H
Front Cell Infect Microbiol; 2022; 12():1074903. PubMed ID: 36569209
[TBL] [Abstract][Full Text] [Related]
5. Interactions between antifungals and everolimus against
Liang P; Song J; Liu Q
Front Cell Infect Microbiol; 2023; 13():1131641. PubMed ID: 37026056
[TBL] [Abstract][Full Text] [Related]
6. Effects of environmental factors on sensitivity of Cryptococcus neoformans to fluconazole and amphotericin B.
Carlson T; Lupinacci E; Moseley K; Chandrasekaran S
FEMS Microbiol Lett; 2021 May; 368(7):. PubMed ID: 33877319
[TBL] [Abstract][Full Text] [Related]
7. In vitro and in vivo efficacies of the azole SCH56592 against Cryptococcus neoformans.
Perfect JR; Cox GM; Dodge RK; Schell WA
Antimicrob Agents Chemother; 1996 Aug; 40(8):1910-3. PubMed ID: 8843302
[TBL] [Abstract][Full Text] [Related]
8. [Short communication: In vitro activity of amphotericin B with fluconazole or voriconazole combinations against Candida albicans isolates].
Oz Y; Akşit F; Kiraz N; Kiremitçi A
Mikrobiyol Bul; 2008 Jan; 42(1):149-55. PubMed ID: 18444574
[TBL] [Abstract][Full Text] [Related]
9. Serotypes of clinical cerebrospinal fluid Cryptococcus neoformans isolates from southern Taiwan and their in vitro susceptibilities to amphotericin B, fluconazole, and voriconazole.
Chang WN; Huang CR; Lei CB; Lee PY; Chien CC; Chang HW; Chang CS; Lu CH
Jpn J Infect Dis; 2004 Jun; 57(3):113-5. PubMed ID: 15218221
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo antifungal activities of FX0685, a novel triazole antifungal agent with potent activity against fluconazole-resistant Candida albicans.
Takahata S; Okutomi T; Ohtsuka K; Hoshiko S; Uchida K; Yamaguchi H
Med Mycol; 2005 May; 43(3):227-33. PubMed ID: 16010849
[TBL] [Abstract][Full Text] [Related]
11. In vitro susceptibility studies of Cryptococcus neoformans isolated from patients with no clinical response to amphotericin B therapy.
Rodero L; Córdoba S; Cahn P; Hochenfellner F; Davel G; Canteros C; Kaufman S; Guelfand L
J Antimicrob Chemother; 2000 Feb; 45(2):239-42. PubMed ID: 10660509
[TBL] [Abstract][Full Text] [Related]
12. In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans.
Barchiesi F; Di Francesco LF; Compagnucci P; Arzeni D; Giacometti A; Scalise G
J Antimicrob Chemother; 1998 Jan; 41(1):59-65. PubMed ID: 9511038
[TBL] [Abstract][Full Text] [Related]
13. Comparative antifungal susceptibility analyses of Cryptococcus neoformans VNI and Cryptococcus gattii VGII from the Brazilian Amazon Region by the Etest, Vitek 2, and the Clinical and Laboratory Standards Institute broth microdilution methods.
Nishikawa MM; Almeida-Paes R; Brito-Santos F; Nascimento CR; Fialho MM; Trilles L; Morales BP; da Silva SA; Santos W; Santos LO; Fortes ST; Cardarelli-Leite P; Lázera MDS
Med Mycol; 2019 Oct; 57(7):864-873. PubMed ID: 30657975
[TBL] [Abstract][Full Text] [Related]
14. Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro.
Franzot SP; Casadevall A
Antimicrob Agents Chemother; 1997 Feb; 41(2):331-6. PubMed ID: 9021188
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of antifungal combination against Cryptococcus spp.
Reichert-Lima F; Busso-Lopes AF; Lyra L; Peron IH; Taguchi H; Mikami Y; Kamei K; Moretti ML; Schreiber AZ
Mycoses; 2016 Sep; 59(9):585-93. PubMed ID: 27135278
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of amphotericin B in combination with flucytosine against flucytosine-susceptible or flucytosine-resistant isolates of Cryptococcus neoformans during disseminated murine cryptococcosis.
Schwarz P; Dromer F; Lortholary O; Dannaoui E
Antimicrob Agents Chemother; 2006 Jan; 50(1):113-20. PubMed ID: 16377675
[TBL] [Abstract][Full Text] [Related]
17. Impact of the order of initiation of fluconazole and amphotericin B in sequential or combination therapy on killing of Candida albicans in vitro and in a rabbit model of endocarditis and pyelonephritis.
Louie A; Kaw P; Banerjee P; Liu W; Chen G; Miller MH
Antimicrob Agents Chemother; 2001 Feb; 45(2):485-94. PubMed ID: 11158745
[TBL] [Abstract][Full Text] [Related]
18. Voriconazole, combined with amphotericin B, in the treatment for pulmonary cryptococcosis caused by C. neoformans (serotype A) in mice with severe combined immunodeficiency (SCID).
Silva EG; Paula CR; de Assis Baroni F; Gambale W
Mycopathologia; 2012 Jun; 173(5-6):445-9. PubMed ID: 22071662
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of posaconazole (Sch 56592) compared with those of itraconazole and fluconazole against 3,685 clinical isolates of Candida spp. and Cryptococcus neoformans.
Pfaller MA; Messer SA; Hollis RJ; Jones RN
Antimicrob Agents Chemother; 2001 Oct; 45(10):2862-4. PubMed ID: 11557481
[TBL] [Abstract][Full Text] [Related]
20. In vitro susceptibility of Candida dubliniensis to current and new antifungal agents.
Quindós G; Carrillo-Muñoz AJ; Arévalo MP; Salgado J; Alonso-Vargas R; Rodrigo JM; Ruesga MT; Valverde A; Pemán J; Cantón E; Martín-Mazuelos E; Pontón J
Chemotherapy; 2000; 46(6):395-401. PubMed ID: 11053905
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
